Samalin E, Ychou M. Neoadjuvant therapy for gastroesophageal adenocarcinoma. World J Clin Oncol 2016; 7(3): 284-292 [PMID: 27298768 DOI: 10.5306/wjco.v7.i3.284]
Corresponding Author of This Article
Emmanuelle Samalin, MD, Digestive Oncology Department, Institut régional du Cancer de Montpellier (ICM), 208 avenue des Apothicaires, 34298 Montpellier, France. emmanuelle.samalin@icm.unicancer.fr
Research Domain of This Article
Oncology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Oncol. Jun 10, 2016; 7(3): 284-292 Published online Jun 10, 2016. doi: 10.5306/wjco.v7.i3.284
Neoadjuvant therapy for gastroesophageal adenocarcinoma
Emmanuelle Samalin, Marc Ychou
Emmanuelle Samalin, Marc Ychou, Digestive Oncology Department, Institut régional du Cancer de Montpellier (ICM), 34298 Montpellier, France
Author contributions: Both Samalin E and Ychou M designed the review and defined the plan and the issues discussed; Samalin E wrote the manuscript; Samalin E and Ychou M revised the manuscript and approved the final version.
Conflict-of-interest statement: Emmanuelle Samalin has received fees for serving as consultant for Roche and Lilly laboratories. Marc Ychou has received fees for serving as consultant for Roche, Lilly and Bayer laboratories.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Emmanuelle Samalin, MD, Digestive Oncology Department, Institut régional du Cancer de Montpellier (ICM), 208 avenue des Apothicaires, 34298 Montpellier, France. emmanuelle.samalin@icm.unicancer.fr
Telephone: +33-4-67613136 Fax: +33-4-67613022
Received: July 29, 2015 Peer-review started: July 31, 2015 First decision: September 28, 2015 Revised: March 24, 2016 Accepted: April 7, 2016 Article in press: April 11, 2016 Published online: June 10, 2016
Core Tip
Core tip: Gastric and esophageal adenocarcinomas are one of the main causes of cancer-related death worldwide. The incidence of gastroesophageal junction adenocarcinoma is rapidly rising in Western countries. Surgical resection is currently the major curative treatment. As the 5-year survival rate highly depends on the pTNM stage, the treatment strategy is very challenging for oncologists. Several treatments, including systemic chemotherapy, are being assessed to prevent recurrences and improve overall survival. New strategies, such as induction chemotherapy followed by preoperative chemoradiotherapy, targeted therapies and new cytotoxic regimens in perioperative chemotherapy, are currently assessed to improve current standards and develop more tailored therapeutic interventions.
